Rapport Therapeutics, Inc./$RAPP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Ticker
$RAPP
Sector
Primary listing
Employees
84
Headquarters
Website
RAPP Metrics
BasicAdvanced
$1.5B
-
-$2.86
-
-
Price and volume
Market cap
$1.5B
52-week high
$42.27
52-week low
$7.73
Average daily volume
342K
Financial strength
Current ratio
26.173
Quick ratio
25.751
Long term debt to equity
1.801
Total debt to equity
2.37
Profitability
EBITDA (TTM)
-124.082
Management effectiveness
Return on assets (TTM)
-18.90%
Return on equity (TTM)
-28.22%
Valuation
Price to book
3.12
Price to tangible book (TTM)
3.12
Price to free cash flow (TTM)
-13.998
Free cash flow yield (TTM)
-7.14%
Free cash flow per share (TTM)
-2.262
Growth
Earnings per share change (TTM)
-24.17%
3-year earnings per share growth (CAGR)
-42.36%
RAPP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rapport Therapeutics, Inc. stock?
Rapport Therapeutics, Inc. (RAPP) has a market cap of $1.5B as of April 02, 2026.
What is the P/E ratio for Rapport Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Rapport Therapeutics, Inc. (RAPP) stock is 0 as of April 02, 2026.
Does Rapport Therapeutics, Inc. stock pay dividends?
No, Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders as of April 02, 2026.
When is the next Rapport Therapeutics, Inc. dividend payment date?
Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders.
What is the beta indicator for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) does not currently have a Beta indicator.